DOWNREGULATION OF TRANSCRIPTION FACTORS BY RIBONUCLEIC ACID INTERFERENCE. A NOVEL APPROACH TO EXTEND THE MULTIPOTENCY OF AUTOLOGOUS ADULT STEM CELLS?
Boon C Heng,Tong Cao
DOI: https://doi.org/10.1290/1543-706x(2004)40<131:dotfbr>2.0.co;2
2004-01-01
Abstract:Dear Editor: Adult stem cells have tremendous potential in regenerative medicine (Hedrick and Daniels, 2003). Because immunorejection is undoubtedly the most formidable challenge in stem cell transplantation therapy (Bradley et al., 2002), the autologous transplantation of adult stem cells is preferred over the allogenic transplantation of either adult or embryonic stem (ES) cells. Although therapeutic cloning for the production of isogenic ES ceils has recently been achieved in the human model (Hwang et al., 2004), there are many outstanding technical difficulties that have to be overcome (Lanza et al., 1999) before this could materialize into a viable mode of clinical therapy. Recent studies have demonstrated the extensive plasticity of adult stem cells, but this remains a highly controversial issue (Verfaillie, 2002; Goodell, 2003; Wagers and Weissman, 2004). In any case, the differentiation capacity of autologous adult stem ceils appears to be strongly biased toward lineages that are characteristic of the tissue or organ from which they originate. With the possible exception of bone marrow-derived mesenchymal stem cells (Jiang et al., 2002), the observed transdifferentiation of all other types of putative adult stem cells seems to be relatively rare and sporadic (Goodell, 2003). Even with bone marrow-derived mesenchymal stem cells, there appears to be a strong bias in differentiation toward a limited number of mesodermal lineages, such as the osteogenic, chondrogenic, myogenic, and adipogenic lineages (Short et al., 2003; Barry and Murphy, 2004). This limited multipotency of adult stem cells could severely restrict their use in autologous cell transplantation therapy. Obviously, it would not be possible to harvest autologous adult stem cells from diseased or damaged tissues and organs that are in dire need of therapeutic intervention. Instead, it would be much more practical to extract autologous adult stem cells from other healthy tissue types and use these to regenerate the damaged or diseased tissue or organ. Hence, it is imperative to develop strategies to confer a higher degree of plasticity on autologous adult stem cells, thereby enabling them to differentiate into a greater variety of other lineages. Only then, can the full potential of autologous adult stem ceils in regenerative medicine be realized. A promising strategy for expanding the plasticity of autologous adult stem cells is through downregulation of gene expression by ribonucleic acid (RNA) interference (Milhavet et al., 2003). Briefly, this is achieved by the hybridization of a short RNA oligonucleotide (micro-RNA or small interfering RNA) with messenger RNA encoding for specific proteins. This results in the formation of a hairpin loop, which blocks protein translation (Milhavet et al., 2003). The interference RNA (iRNA) can either be encoded by transfected recombinant deoxyribonucleic acid (DNA) (Wilson and Richardson, 2003) or be delivered directly into the cell (Capodici et al., 2002; Well et al., 2002; Zhang et al., 2004). Because there are oven'iding safety concerns regarding the direct application of recombinant DNA technology in human clinical therapy (Reid et al., 2002), it is preferable to deliver iRNA directly into the cell for therapeutic applications. In that case, the effects of RNA interference are only transient, lasting on average three to five cell doublings (McManus and Sharp, 2002). However, this relatively short duration could be sufficient to redirect stem cell commitment to another lineage, if there is also simultaneous exposure to appropriate stimuli within the in vivo environment on transplantation in situ or within ex vivo culture. The targets of choice for RNA interference are likely to be transcription factors that exert upstream control of somatic differentiation (Scbrem et al., 2002; Shirasaki and Pfaff, 2002; Sachinidis et al., 2003). These can be thought of as "master switches" that control the expression of the entire array of proteins that are characteristic or specific to a particular lineage. Indeed, numerous transcription factors have been implicated in early lineage commitment of adult stem cells (Schrem et al., 2002; Shirasaki and Pfaff, 2002; Sachinidis et al., 2003). For example, with bone marrow-derived mesenchymal stem cells, Sox9 determines early commitment to the chondrogenic lineage (Ng et al., 1997; Akiyama et al., 2002), whereas Runx and Osterix determine early commitment to the osteogenic lineage (Nakashima et al., 2002; Lian et al., 2003). Hence, if RNA interference technology is used to downregulate the expression of these transcription factors, the predisposition of mesenchymal stem cells to differentiate into the chondrogenic and osteogenic lineages could possibly be reduced. This in turn could result in mesenchymal stem ceils becoming more pliable to transdifferentiate into other lineages, thereby expanding their degree of plasticity. The major challenge in attempting to apply RNA interference in stem cell transplantation therapy is the delivery of iRNA into stern cells. As mentioned earlier, there are serious safety concerns regarding transfecting stem ceils with recombinant DNA encoding for iRNA. Hence, the only alternative appears to be direct delivery of iRNA into the cells. At present, the delivery method of choice is through the use of lipophilic agents (Capodici et al., 2002; Well et ah, 2002; Zhang et al., 2004), but this suffers frmn relatively low efficiency, especially with primary cell cultures (McManus and Sharp, 2002). Hence, it is imperative to enhance the transfection efficiency of iRNA into primary cells, if this technology is to be applied to stem cell transplantation medicine. Currently, there are no reported studies on the use of RNA interference to extend the multipotency of adult stem cells. It is hoped